The 2016 version of the WHO classification criteria for glioma combined genotypic parameters with traditional histology and included IDH mutation, ATRX mutation, 1p/19q deletion, and TP53 mutation as classification factors2,26–28. Here, ATRX is linked to central nervous system cancer.